Format

Send to

Choose Destination
Int J Mol Sci. 2014 Nov 14;15(11):21136-54. doi: 10.3390/ijms151121136.

The eTOX data-sharing project to advance in silico drug-induced toxicity prediction.

Author information

1
Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona E-08003, Spain. montserrat.cases@bayer.com.
2
Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds LS11 5PS, UK. katharine.briggs@lhasalimited.org.
3
Investigational Toxicology, Bayer HealthCare, Müllerstraße 178, Berlin D-13353, Germany. thomas.steger-hartmann@bayer.com.
4
PreClinical Safety, Novartis Institute for Biomedical Research, Klybeckstrasse 141, Basel CH-4057, Switzerland. francois.pognan@novartis.com.
5
PreClinical Safety, Novartis Institute for Biomedical Research, Klybeckstrasse 141, Basel CH-4057, Switzerland. philippe.marc@novartis.com.
6
Molecular Networks GmbH, Medical Valley Center, Henke strasse 91, Erlangen 91052, Germany. kleinoeder@molecular-networks.com.
7
Molecular Networks GmbH, Medical Valley Center, Henke strasse 91, Erlangen 91052, Germany. schwab@molecular-networks.com.
8
Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona E-08003, Spain. manuel.pastor@upf.edu.
9
Investigational Toxicology, Bayer HealthCare, Müllerstraße 178, Berlin D-13353, Germany. joerg.wichard@bayer.com.
10
Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, C/Dr. Aiguader 88, Barcelona E-08003, Spain. fsanz@imim.es.

Abstract

The high-quality in vivo preclinical safety data produced by the pharmaceutical industry during drug development, which follows numerous strict guidelines, are mostly not available in the public domain. These safety data are sometimes published as a condensed summary for the few compounds that reach the market, but the majority of studies are never made public and are often difficult to access in an automated way, even sometimes within the owning company itself. It is evident from many academic and industrial examples, that useful data mining and model development requires large and representative data sets and careful curation of the collected data. In 2010, under the auspices of the Innovative Medicines Initiative, the eTOX project started with the objective of extracting and sharing preclinical study data from paper or pdf archives of toxicology departments of the 13 participating pharmaceutical companies and using such data for establishing a detailed, well-curated database, which could then serve as source for read-across approaches (early assessment of the potential toxicity of a drug candidate by comparison of similar structure and/or effects) and training of predictive models. The paper describes the efforts undertaken to allow effective data sharing intellectual property (IP) protection and set up of adequate controlled vocabularies) and to establish the database (currently with over 4000 studies contributed by the pharma companies corresponding to more than 1400 compounds). In addition, the status of predictive models building and some specific features of the eTOX predictive system (eTOXsys) are presented as decision support knowledge-based tools for drug development process at an early stage.

PMID:
25405742
PMCID:
PMC4264217
DOI:
10.3390/ijms151121136
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center